Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21766238 | 0.89 | ADORA2B (0.58) | ADORA2BLMNARXFP1SMN1; SMN2MAPT | |
| SCHEMBL17744966 | 0.82 | ADORA1 (0.75) | ADORA1ADORA2BLMNARXFP1MAPT | |
| SCHEMBL19499802 | 0.80 | ADORA1 (0.61) | ADORA1ADORA2BLMNARXFP1SMN1; SMN2 | |
| SCHEMBL17748272 | 0.77 | ADORA1 (0.76) | ADORA1ADORA2BLMNARXFP1MAPT | |
| SCHEMBL19499799 | 0.77 | ADORA1 (0.62) | ADORA1ADORA2BLMNARXFP1SMN1; SMN2 | |
| SCHEMBL16120984 | 0.71 | ADORA2B (0.81) | ADORA1ADORA2BLMNARXFP1SMN1; SMN2 | |
| SCHEMBL18175139 | 0.71 | ADORA2B (0.71) | ADORA1ADORA2BLMNARXFP1SMN1; SMN2 | |
| SCHEMBL28025751 | 0.70 | ADORA2B (1.00) | ADORA2BLMNARXFP1SMN1; SMN2MAPT | |
| SCHEMBL19472287 | 0.70 | AMPD2 (0.38) | ADORA2BLMNAADORA2AKMT2A | |
| Etofylline SCHEMBL149271 | 0.69 | ADORA2B (1.00) | ADORA2BLMNARXFP1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10226467-B2 | Compounds for the treatment of myotonic dystrophy | UNIVERSITAT DE VALENCIA (ES) | 2019-03-12 | — | — | US | disclosed |
| US-20170312285-A1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | SELABTEC SCIENCES, SL (ES) | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312285-A1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | SMN1; SMN2, CPT1B, MTPN | ADORA1 790/4885ADORA2B 1199/4885LMNA 433/4885 |
| US-10226467-B2 | Compounds for the treatment of myotonic dystrophy | SMN1; SMN2, CPT1B, MTPN | ADORA1 790/4885ADORA2B 1199/4885LMNA 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.